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Vav family proteins are members of the Dbl family of
guanine nucleotide exchange factors and activators of
Rho family small GTPases. In addition to the Dbl homol-
ogy (DH) domain important for guanine nucleotide ex-
change factor catalytic function, all Dbl family proteins
contain an adjacent pleckstrin homology (PH) domain
that serves to regulate DH domain activity. Although the
role of the PH domain in Vav function has been evalu-
ated extensively, its precise role and whether it serves a
distinct role in different Vav proteins remain unre-
solved. Additionally, the precise role of an adjacent cys-
teine-rich domain (CRD) in regulating DH domain func-
tion is also unclear. In this study, we evaluated the
contribution of these putative protein-protein or pro-
tein-lipid interaction domains to Vav signaling and
transforming activity. In contrast to previous observa-
tions, we found that the PH domain is critical for Vav
transforming activity. Similarly, the CRD was also es-
sential and served a function distinct from that of the
PH domain. Although mutation of either domain re-
duced Vav membrane association, addition of plasma
membrane targeting sequences to either the CRD or PH
domain mutant proteins did not restore Vav transform-
ing activity. This result contrasts with other Dbl family
proteins, where a membrane targeting sequence alone
was sufficient to restore the loss of function caused by
mutation of the PH domain. Furthermore, green fluores-
cent protein fusion proteins containing the PH domain
or CRD, or both, failed to target to the plasma mem-
brane, suggesting that these two domains also serve reg-
ulatory functions independent of promoting membrane
localization. Finally, we found that phosphatidylinositol
3-kinase activation may promote Vav membrane associ-
ation via phosphatidylinositol 3,4,5-triphosphate bind-
ing to the PH domain.
Vav is a member of the Dbl family of proteins that function
as guanine nucleotide exchange factors (GEFs)1 (1–3) and ac-
tivators of Rho family small GTPases (4, 5). Rho family protein
function is controlled by a regulated GDP/GTP cycle. Whereas
Dbl family proteins function as GEFs and stimulate the forma-
tion of the active GTP-bound protein, GTPase activating pro-
teins promote formation of the inactive GDP-bound protein.
The GTP-bound protein is the active form and interacts with a
spectrum of downstream effector targets to stimulate signaling
pathways that regulate actin cytoskeletal organization, gene
expression, and cell cycle progression (6). Vav was first identi-
fied as a transforming protein where NH2-terminal truncation
of negative regulatory sequences converted Vav into a consti-
tutively activated GEF. Subsequently, two closely related pro-
teins, Vav2 and Vav3, were identified that shared strong se-
quence similarity (approximately 70%) and structural
topography with Vav. Overlapping, as well as very distinct,
functions have been described for the different Vav proteins (7).
All Dbl family proteins share a catalytic Dbl homology (DH)
that is followed invariantly by a pleckstrin homology (PH)
domain (1, 3). The DH domains of Vav proteins function as
GEFs for multiple Rho family proteins, including RhoA, RhoG,
Rac1, and Cdc42 (8–14). Although PH domains can be found on
signaling molecules other than Dbl family proteins (15), the
invariant DH/PH domain organization suggests that the PH
domain serves as a critical regulator of DH domain function.
Current evidence suggests two roles for the PH domain in
regulating DH domain function. First, the mutation of the PH
domains of several Dbl family proteins (Lfc and Dbs) has been
shown to abolish their transforming activity, and the addition
of the plasma membrane targeting sequence of Ras proteins
can restore transforming activity (16, 17). In contrast, the
critical function of the PH domain of Dbl could not be restored
by addition of a plasma membrane targeting sequence (18).
Thus, the PH domain can serve simply as a membrane target-
ing sequence for some but not all Dbl family proteins. Whether
the PH domain of Vav serves such a role has not been
determined.
A second function of the PH domain may be to serve as a
negative, intramolecular regulator of DH domain function.
Broek and colleagues found that the PH domain of Vav, like
other PH domains (19), can bind phosphatidylinositol 4,5-bi-
phosphate (PIP2) and phosphatidylinositol 3,4,5-triphosphate
(PIP3) (20, 21). Whereas PIP2 association with proto-Vav did
not promote its GEF function, PIP3-mediated dissociation of
PIP2 binding enhanced its GEF function in vitro. Mutations in
the PH domain that impaired PIP2/PIP3 binding caused in-
creased GEF function. Thus, a model was proposed where PIP2
association with the PH domain served as a negative regulator
of DH domain function, and the loss of PIP2 binding caused by
PIP3 binding relieved this negative regulation. Consistent with
a negative regulatory role, Abrams and colleagues (22) found
that mutation of the PH domain of full-length Vav led to a
constitutively activated protein. In contrast, the PH domain
* This work was supported by National Institutes of Health Grants
CA42978, CA55008, and CA63071 (all to C. J. D.). The costs of publi-
cation of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ To whom correspondence should be addressed: University of North
Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, CB
7295, Chapel Hill, NC 27599-7295. Tel.: 919-966-5634; Fax: 919-966-
0162; E-mail: cjder@med.unc.edu.
1 The abbreviations used are: GEF, guanine nucleotide exchange
factor; DH, Dbl homology; PH, pleckstrin homology; SH2, Src homology
2; SH3, Src homology 3; CRD, cysteine-rich domain; GFP, green fluo-
rescent protein; PI3K, phosphatidylinositol 3-kinase; PIP2, phosphati-
dylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphos-
phate; PKC, protein kinase C; HA, hemagglutinin; DMEM, Dulbecco’s
modified Eagle’s medium; PBS, phosphate-buffered saline.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 277, No. 42, Issue of October 18, pp. 39350–39359, 2002
© 2002 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org39350
This is an Open Access article under the CC BY license.
was found to be dispensable for Vav3 biological activity (13),
whereas we recently determined that the PH domain served a
critical positive regulatory role for Vav2 function (23). These
observations suggest the possibility that the PH domain serves
divergent functions for the closely related Vav proteins.
Beyond the DH/PH domain structure, Dbl family proteins
show little or no sequence similarities in their remaining se-
quences (1, 3). In addition to the DH and PH domains, Vav
family proteins also contain a diverse array of putative protein-
protein or protein-lipid interaction domains that can poten-
tially serve as negative or positive regulators of Vav function
(reviewed in Refs. 7 and 24). The NH2 terminus of Vav contains
a leucine-rich, calponin homology and an acidic amino acid-rich
domain. Because NH2-terminal truncation of these sequences
converts Vav to a potent transforming protein, these sequences
serve as negative regulators of Vav function (25, 26). Following
the PH domain, Vav contains a cysteine-rich domain (CRD),
two Src homology 3 (SH3) domains, and a SH2 domain at its
COOH terminus (27). This domain organization is conserved in
all three Vav family proteins. Although introduction of mis-
sense mutations into the SH2 and SH3 domains caused a loss
of Vav transforming activity (28, 29), subsequent deletion anal-
yses showed that all the SH2/SH3 domains were dispensable
for the transforming activity of all three Vav proteins (10, 13,
23). The basis for these contrasting observations is not known.
In contrast to the SH domains, either missense mutation or
deletion of the CRD has shown that this domain is critical for
the biological function of all three Vav proteins (10, 13, 23, 30).
Although the precise role of the CRD in Vav function still
remains to be elucidated, CRDs in other proteins have been
shown to facilitate translocation to the plasma membrane, e.g.
the CRDs of protein kinase C or RasGRP proteins bind diacyl-
glycerol and phorbol esters, which in turn promote their trans-
location to the plasma membrane (31–33). Mutation of the CRD
of RasGRP causes a loss of transforming activity, and addition
of a plasma membrane targeting sequence can restore the loss
of CRD function. Although the CRD of the Raf-1 serine/threo-
nine kinase does not bind diacylglycerol or phorbol esters, it
can interact with Ras to facilitate Raf-1 association with the
plasma membrane to allow activation of its kinase function
(34). The CRD of Raf-1 also binds the 14-3-3 adaptor protein as
well as phospholipids. Thus, although the CRD of Vav does not
bind diacylglycerol, it may still serve as a protein-protein or
protein-lipid interaction domain that facilitates Vav associa-
tion with the plasma membrane.
Despite extensive analyses, the precise contribution and
functions of the PH domain and CRD to Vav signaling and
transformation remain unclear. Conflicting observations have
been made that may reflect differences in experimental analy-
ses. To attempt to clarify the role of these two domains in
regulating Vav DH domain function, we have evaluated their
functions within the context of the minimal functional unit of
Vav, the DH/PH/CRD fragment. This approach avoids poten-
tial complications that may arise from the presence of other
interaction domains present in Vav. Another issue that we
have addressed is whether these domains serve similar or
distinct functions for other Vav proteins. To accomplish this,
we have taken the identical approaches that we have used
recently to study the role of the PH domain and CRD in Vav2
function (23). We found that, identical to our observations with
Vav2, the PH domain and CRD of Vav are both critical for Vav
biological activity. Thus, we find no isoform differences in PH
domain or CRD function for Vav proteins. Additionally,
whereas both domains do facilitate DH domain association
with membranes, alone they do not function as membrane
targeting sequences nor can their functions be replaced by
plasma membrane targeting sequences. Finally, we deter-
mined a limited role for PI3K activation in promoting Vav
membrane association and activity.
EXPERIMENTAL PROCEDURES
Molecular Constructs—cDNA sequences encoding mutations in the
SH3 domains were made using the Chameleon site-directed mutagen-
esis kit (Stratagene). Mouse proto-vav cDNA sequences subcloned into
the mammalian expression vector pCTV3HA, which contains sequences
from a hemagglutinin (HA) epitope tag at its NH2 terminus, has been
described previously (16, 30). A 730-base pair (bp) HpaI fragment
containing a unique BamHI site at the COOH-terminal end of Vav, just
prior to the start of the first SH3 domain, was generated by polymerase
chain reaction (PCR). This fragment was ligated to the pCR 2.1 vector
from the TA cloning kit (Stratagene), sequenced, and then used as the
template DNA for mutagenesis. To generate the single mutations
within each SH3 domain (W636K and W820K), mutagenic primers
(5-ATT CCT TCC CTC CCA CTT GTT GTG CTC AGC CTC and 5-GAT
CTC CCC ACG CCA CTT GCC TTG CTG TCC) were used, respectively,
along with a XhoI3 ClaI selection site primer (5-CCC TCT AGA TGC
ATG ATC GAT CGG CCG CCA GTG). When the mutations were veri-
fied by sequencing, the double mutant was constructed by using the
W820K mutant sequence as a template, the W636K mutagenic primer,
and a second HindIII 3 SalI selection site primer (5-GCT CGG TAC
CGT CGA CGG CGT AAT CAT GG). The pCR 2.1 plasmids containing
the correct mutations were then digested with HpaI and ligated to
pCTV3HA. This plasmid was then digested with BamHI and a 2.3-
kilobase (kb) fragment containing the appropriate mutations, and 1.5
kb of the COOH terminus of pCTV3HA was isolated. To complete the
sequences with the NH2-terminal portion of vav, pCTV3HA N-186 vav
(described in Ref. 26), was digested with BamHI and the NH2-terminal
sequences were ligated to the SH3 domain mutant BamHI fragments.
N-186 vav C was constructed in a similar fashion as was done for
proto-vavC (described in Ref. 26), except that a FseI/BsiWI N-186 vav
fragment was used instead of a FseI/BsiWI proto-vav fragment.
cDNA sequences encoding amino acid substitutions in the PH do-
main were generated by PCR-mediated oligonucleotide site-directed
mutagenesis. These constructs all terminated just prior to the first SH3
domain similar to the N-186 VavC mutants. Because the lysine
residue at position 404 lies close to the unique FseI site in Vav, the
K404A PH mutant could be made directly from the 5 primer (5-CA
GTT AAC GGC CGG CCC GCG ATT GAC GGT GAG CTC). The 3
primer corresponding to amino acids 594–600 (3-CA GTT AAC CTA
CTA GGA TCC CTT AGG CAG ACC CAA TTC) contains two stop
codons flanked by a BamHI site and a HpaI site at the 3 end. The
W495L mutant was generated by four primer PCR using the unique
FseI site. Two fragments were generated, a 280-bp fragment (5-CA
GTT AAC GGC CGG CCC AAG ATT GAC GGT GAG and 3-CG AAC
TGT TCC ATC AGC TTC TTC TTC AGC) and a 330-bp fragment
(5-GAG CTG AAG AAG AAG CTG ATG GAA CAG TTC G and 3-CAG
GCC GGC CAG GAT CCC ATA GTA TTC CTG AAA CAC TT), which
were then annealed together and amplified by PCR. Sequences encod-
ing both PH mutants K404A and W495L were contained in a 610-bp
fragment, which was then digested with HpaI and ligated into the
pCTV3HA plasmid. This plasmid was digested with FseI/BsiWI and
ligated to the pCTV3HA N-186 FseI/BsiWI fragment to complete the
construct.
The pCTV3HA N-186 vavCRD mutant was constructed by PCR
utilizing the same 5 primer used for the W495L PH domain mutant
and a 3 primer (3-CA GTT AAC CTA CTA GGA TCC CCC ATT GGC
TGT AGC ATT) corresponding to residues 509–515 with two stop
codons flanked by a BamHI and a HpaI site at the 3 end. This 333-bp
fragment was digested with HpaI and ligated into pCTV3HA. To add
the remaining NH2-terminal sequences, the pCTV3HA construct was
digested with FseI/BsiWI and ligated to the FseI/BsiWI fragment from
pCTV3HA N-186 vav.
To make membrane targeting versions of N-186 vavC PH(K404A),
N-186 vavC PH(W495L), and N-186 vavCRD, sequences encoding
the last 18 remaining amino acids from K-ras4B (includes a polylysine-
rich region and the CAAX prenylation signal CVIM) were ligated to
each construct at the BamHI restriction enzyme site just prior to the
tandem stop codons. Briefly, two primers corresponding to the afore-
mentioned K-ras4B sequences (5-CA GTT AAC GGA TCC AGC AAA
GAT GGT AAA AAG AAG AAA AAG AAG TCA AAG ACA AAG TGT
GTA ATT ATG TAA; 3-CA GTT AAC TTA CAT AAT TAC ACA CTT
TGT CTT TGA CTT CTT TTT CTT CTT TTT ACC ATC TTT GCT)
containing HpaI restriction enzyme sites at each end and a novel
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BamHI at the 5 end were annealed together and then digested with
HpaI. The 75-bp fragment was ligated to a HpaI-digested pCTV3HA
expression vector (pCTV3HA vav-CAAX). Because the cognate vector
pCTV3HA contains a unique BamHI restriction enzyme site down-
stream from its multiple cloning site, digestion of pCTV3HA vav-CAAX
with BamHI derives a 1.6-kb fragment that can be ligated to the BamHI
site introduced into the mutated PH domain and CRD constructs.
The green fluorescent protein (GFP) fusion expression constructs of
the vav PH, CRD, and PH/CRD domains were constructed by PCR
amplification of these regions from the cDNA sequence in N-186 vav in
pAX142. The PH domain containing amino acids 368–517 was ampli-
fied with primers incorporating an in-frame 5 XhoI restriction site and
a stop codon adjacent to a 3 HindIII site. The CRD and PH/CRD
encoding fragments were created in similar fashions to include amino
acids 507–573 and 368–573, respectively. The digested fragments were
ligated into the XhoI/HindIII sites of the pEGFP-C3 mammalian ex-
pression vector (Clontech). The products were verified by sequencing.
Cell Culture and Transformation Assays—NIH 3T3 mouse fibro-
blasts and 293T human kidney epithelial cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented with 10% calf
serum or fetal calf serum, respectively. DNA transfections were per-
formed by calcium phosphate precipitation method as described previ-
ously (35). For transformation studies, the cognate empty vector was
used as a control. The transfected cultures were maintained in culture
for 14 days, fixed, and stained with crystal violet (0.5%), and then the
number of foci of transformed cells was quantitated. To establish cell
lines that stably expressed the Vav mutants, transfected NIH 3T3 cells
were selected in growth medium supplemented with hygromycin (400
g/ml) and multiple drug-resistant colonies (100) were pooled to-
gether after 10 days of selection to establish mass populations of stably
transfected cells.
Transient Expression Reporter Gene Assays—Transient transfections
using various reporter plasmids to determine transcriptional activity
were performed as described previously (36). NIH 3T3 cells were trans-
fected by calcium phosphate precipitation, allowed to recover for 30 h,
and were then serum-starved (0.5% calf serum) for 14–15 h before
lysing with luciferase lysis buffer (Amersham Biosciences). For the
N-186 Vav and p110-CAAX cooperation assays, NIH 3T3 cells were
transfected with LipofectAMINE Plus reagent (Invitrogen) according to
the protocol from the manufacturer. After transfection, these cells were
treated exactly as described above. The p110-CAAX construct was de-
scribed previously (37). The lysates were analyzed using enhanced
chemiluminescent reagents and a Monolight 2010 luminometer (Ana-
lytical Luminescence). All the assays were performed at least in
triplicate.
Membrane Fractionation Analyses—Subcellular fractionation was
performed as described previously (26). 293T cells were transiently
transfected with 3 g of the pAX142 empty vector or pAX142 constructs
encoding N-186 Vav, N-186 VavC, the N-186 VavC PH domain
mutants, and the N-186 VavCRD mutants. After transient transfec-
tion, 293T cells were grown for 48 h, then gently washed twice with
ice-cold phosphate-buffered saline (PBS), and resuspended in 1 ml of
cold TSA buffer (2 mM Tris, pH 8.0, 0.14 M NaCl, 0.25 M sucrose, 1 mM
EDTA, 100 g/ml phenylmethylsulfonyl fluoride, 25 g/ml leupeptin).
The cells were homogenized and centrifuged (15,000  g) to acquire
total (T) protein (200 l of supernatant). The remaining supernatant
was then centrifuged (100,000  g) in a Beckman TLS-55 rotor for 2 h
to separate the supernatant into crude cytosolic (S100) and membrane
and cytoskeletal protein containing (P100) fractions. The protein con-
centrations of the total, cytosolic, and membrane samples were deter-
mined using a BCA protein assay kit (Pierce). Protein fractions (25 g)
were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE),
transferred to Immobilon-P membranes, and probed with anti-HA
epitope antibody (Babco).
Protein Analysis—Protein concentrations of the transiently trans-
fected 293T cells or in the NIH 3T3 cells stably expressing the Vav
mutants were determined by the BCA kit (Pierce). Protein expression
was determined by Western blot analysis and detected by chemilumi-
nescence (Amersham Biosciences) and the anti-HA epitope antibody as
described previously (38).
Confocal Microscopy—NIH 3T3 cells were transiently transfected
with pEGFP-C3 vector or pEGFP-C3 constructs encoding GFP-Vav PH,
GFP-Vav PH/CRD, or GFP-Vav CRD, or the previously reported
pEGFP-C1 Akt-PH and pEGFP-N1 PKC-C1A-(26–89) (39, 40). Trans-
fections were carried out with LipofectAMINE Plus reagent (Invitro-
gen) following the suggested protocol. After transfection, cells were
grown in DMEM with 10% calf serum for 6 h and then serum-starved in
DMEM for 18 h. The cells were washed once with PBS and kept in PBS
for visualization of live cells. For dishes that were serum-stimulated,
images were taken 60 s after addition of PBS supplemented with 10%
calf serum. Microscopy was performed on an Olympus Fluoview FV 300
laser scanning biological microscope. Images are stacks of serial scans
taken through each cell at 0.4-m thickness.
RESULTS
The DH/PH/CRD Is the Minimal Functional Transforming
Fragment of Vav—Previous studies showed that point muta-
tions in the SH2 domain or the COOH-terminal SH3 domain
decreased Vav transforming activity (28–30), whereas other
studies found that deletion of the entire SH3/SH2/SH3 do-
mains of Vav proteins did not cause loss of transforming activ-
ity (10, 13, 23). The basis for these opposite observations is not
clear but may reflect different consequences of missense and
deletion mutagenesis, or alternatively, differences in Vav con-
structs used. To distinguish between these possibilities, we
compared the consequences of missense and deletion mutations
of the SH3 domains of the NH2-terminal truncated and highly
transforming N-186 Vav mutant protein.
Mutation of the conserved tryptophan present in a majority
of SH3 domains to lysine has been shown to disrupt the func-
tion of other SH3 domains (41, 42). We made the analogous
mutations at residue 636 (W636K) in the NH2-terminal SH3
domain or at residue 820 (W820K) in the COOH-terminal SH3
(Fig. 1). We also made a Vav mutant with mutations in both
SH3 domains (W636K/W820K) as well as a N-186 Vav mutant
that lacked the entire SH3/SH2/SH3 region (N-186 VavC).
First, we determined whether the different point or deletion
mutations caused any significant alterations in protein stabil-
ity. Western blot analyses of cells transiently (Fig. 2) or stably
(data not shown) expressing each SH3 mutant showed that
each HA epitope-tagged Vav proteins was expressed at compa-
rable levels. Thus, differences in biological activity would not
be influenced by differences in protein stability or level of
expression. We next performed focus formation transformation
assays in NIH 3T3 cells to evaluate the effect of the SH3
FIG. 1. Domain structure of the N-186 Vav COOH-terminal
point and deletion mutants. Shown are the domain structure of
full-length Vav (proto-Vav), and the SH3 domain, CRD, and PH domain
mutants. Figure shows calponin homology (CH) domain, acidic domain
(AD), DH domain, PH domain, CRD, SH3 and SH2 domains, and
18-amino acid plasma membrane targeting sequence from K-Ras4B
(CAAX). The lines below proto-Vav show the predicted translational
products of the various Vav mutants. The amino acid substitutions are
shown below the lines. All the mutants were constructed within N-186
Vav and fused in-frame to a HA epitope tag at the NH2 terminus. NIH,
focus-forming activity in NIH 3T3 transfection assays: , 100% or
more of activity of N-186 Vav (4  10 (3) foci/pmol); , 25–50% of
N-186 Vav; /  10% of N-186 Vav; , no focus-forming activity.
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domain mutations, as well as removal of the entire SH3/SH2/
SH3 region, on Vav transforming activity (Fig. 3). We found
that the transforming activities of the N-186 Vav
SH3(W636K) and N-186 Vav SH3(W636K/W820K) mutants
were decreased 3–6-fold, respectively. In contrast to the de-
creased activity described in a previous study (28), we found
that the N-186 Vav SH3(820K) mutant showed an enhanced
focus-forming ability. However, when we deleted the entire
SH3/SH2/SH3 domain (N-186 VavC), we were surprised to
see that it was enhanced significantly in transforming activity.
These results suggest that a functional NH2-, but not COOH-,
terminal SH3 domain, within the context of the intact SH3/
SH2/SH3 domains, is required for full Vav transforming activ-
ity. However, the potent transforming activity of N-186
VavC clearly demonstrates that all three SH domains are
dispensable for Vav transforming activity. Thus, we suspect
that the different consequences of the SH3 domain point mu-
tations may be the result of indirect consequences on adjacent
domains. Finally, no transforming activity was detected with
the SH domains were deleted from proto-Vav (proto-VavC),
indicating that, unlike deletion of the NH2-terminal sequences,
deletion of COOH-terminal sequences does not result in con-
stitutively activated Vav proteins.
The PH Domain Alone Is Not Sufficient to Support DH Do-
main Transformation—Point mutations that disrupt the struc-
ture of the CRD of Vav have been shown previously to decrease
the transforming activity of onco-Vav (30). However, because
we observed that point mutations and deletion mutants in the
SH3/SH2/SH3 domain region of Vav had different conse-
quences on Vav transforming activity, we determined whether
complete deletion of the CRD would also cause a loss of Vav
function. The previously described CRD mutations were made
in a version of Vav that retained the SH3/SH2/SH3 domains.
Therefore, we generated a mutant of the N-186 VavC mu-
tant that lacked the CRD (N-186 VavCRD) (Fig. 1). Similar
to previous observations made with point mutations in the
CRD of Vav, we found that N-186 VavCRD lacked any
detectable focus-forming activity (Fig. 3).
By analogy to the CRDs of PKC and Raf-1, the CRD may bind
phospholipids and serve to promote Vav membrane association
(32, 43). To address this possibility, we determined whether
removal of the CRD altered Vav membrane association and
whether addition of a plasma membrane-targeting sequence
could restore the transforming activity of N-186 VavCRD. A
chimeric protein was generated, where the 18 COOH-terminal
amino acids of K-Ras4B were added onto the COOH terminus
of N-186 VavCRD (designated N-186 VavCRD-CX) (Fig.
1). This sequence signals for the farnesylation and other post-
translational modifications of K-Ras4B and can target heterol-
ogous proteins to the plasma membrane (44). Protein expres-
sion was determined by Western blot analysis using cell lysates
from 293T cells transiently transfected with the CRD mu-
tants (Fig. 2) and from cell lysates of NIH 3T3 cells stably
expressing these mutants (data not shown) and verified that
these CRD variants were not altered in protein stability.
We first evaluated whether Vav membrane association was
altered upon removal of the CRD and whether addition of the
membrane targeting sequence restored membrane association.
We performed crude subcellular fractionation (100,000  g)
with cell lysates from 293T cells transiently transfected with
the Vav CRD mutants (Fig. 4). We saw significant reduction
in membrane association with the deletion of the CRD.
Whereas N-186 VavC was found predominantly in the P100
membrane (and cytoskeletal protein-containing) fraction (80%)
(Fig. 5), the N-186 VavCRD mutant was found predomi-
nantly in the S100 cytosolic fraction (66%), and showed a 40%
shift from membrane to cytosolic fractions (Fig. 4). These re-
sults support a role for the CRD in facilitating Vav association
with membranes or cytoskeletal components. However, the
N-186 VavCRD-CX mutant was found equally distributed
between the S100 and P100 fractions. Therefore, we saw only a
partial restoration of membrane association with the mem-
brane-targeted version of the Vav CRD mutant. These exper-
iments were repeated with NIH 3T3 cells stably expressing the
Vav CRD mutants, and similar results were observed, sug-
gesting the high degree of overexpression in the transient as-
says did not interfere with localization of the mutants (data not
shown). Finally, the addition of a membrane targeting se-
quence to the DH/PH domains of Vav did not restore trans-
forming activity (Fig. 3). These results suggest that the CRD
does serve a critical role in Vav transformation that is not sub-
stituted for by a plasma membrane targeting sequence. These
observations contrast with our previous studies of the CRD of
RasGRP, where a plasma membrane targeting sequence did re-
store the loss of function caused by mutation of the CRD (33).
We showed previously that the highly transforming mutant
N-186 Vav could stimulate the transcriptional activity of the
Elk-1, Jun, and SRF transcription factors (26). Therefore, we
next assessed the ability of the Vav CRD mutants to stimu-
late these transcriptional activities to determine whether the
loss of transforming activity was associated with the loss of a
particular signaling pathway. However, we found that deletion
of the CRD abolished the ability of Vav to activate any of these
signaling pathways (data not shown). Furthermore, we did not
see any restoration of these activities with the membrane-
targeted N-186 VavCRD-CX mutant. Therefore, our data
suggest that the CRD is critical for mediating the Vav signaling
FIG. 2. Expression of Vav SH3 mutants (panel A) and Vav PH
domain and CRD mutants (panel B) in 293T cells. 293T cells
were transiently transfected with the cognate empty pAX142 mamma-
lian expression vector or pAX142 encoding the indicated proteins. Cell
lysates (25 g) were assayed for protein expression by Western blot
analyses with the anti-HA epitope antibody.
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required for its transforming activity. Thus, Vav contrasts with
the majority of other Dbl family proteins where the tandem
DH/PH domains alone are sufficient for activity in vivo.
Mutation of the PH Domain Disrupts Vav Signaling and
Transforming Activity—In contrast to the essential role of the
PH domain in the function of most Dbl family proteins, muta-
tional analyses showed that the PH domain of Vav family
proteins serves as a negative regulator of DH domain function
(22) and, hence, was found to be dispensable for Vav and Vav3
transforming activity (13, 20). In light of our recent determi-
nation that the PH domain is critical for the transforming
activity of the related Vav2 protein (23), suggesting distinct
functional roles for the PH domain in Vav isoforms, we initi-
ated studies to further evaluate the importance of the PH
domain in Vav function. We performed these studies with the
equivalent DH/PH/CRD fragment of Vav (N-186 VavC) as
we did with Vav2 to avoid complications from other adjacent
interaction domains and to allow us to compare our results
with Vav and Vav2.
We introduced two PH domain mutations into N-186
VavC (Fig. 1). First, we mutated the tryptophan residue pres-
ent in the Vav PH domain (W495L) that corresponds to the
conserved tryptophan residue found in all PH domains (desig-
nated N-186 VavC PH(W495L)). This mutation is expected
to cause a drastic reduction in PH domain structure and func-
tion (41, 42). Second, we also introduced a mutation at a lysine
residue (K404A) that was shown previously to be important for
Vav PH domain binding of phosphoinositides (designated N-
186 VavC PH(K404A)) (20). Broek and colleagues (20) showed
previously that the K404A mutation greatly impaired PIP2
binding in vitro. In anticipation that disruption of PH domain
function will impair Vav membrane association, we also gen-
erated membrane-targeted versions of these PH domain mu-
tants (Fig. 1). Western blot analyses of transiently transfected
293T cells (Fig. 2) or stably transfected NIH 3T3 cells (data not
shown) were done to verify that the introduced mutations did
not perturb protein stability.
Because the PH domain has been shown to contribute to the
membrane association of at least some Dbl family proteins (16,
17), we performed crude subcellular fractionations to deter-
mine the effects of the PH domain mutations on Vav membrane
association (Fig. 5). Although both PH domain mutations
FIG. 3. The SH2 and SH3 domains,
but not CRD, are dispensable for Vav
transformation. NIH 3T3 cells were
transfected with pAX142 expression plas-
mids encoding the various SH3 domain
mutants of Vav (30 ng of DNA/60-mm
dish). Focus-forming activity was scored
14 days after transfection. The values
represent the average 	 standard error of
three dishes. These results were normal-
ized to the number of foci per picomole of
transfected DNA to account for differ-
ences in plasmid size, but this did not
significantly alter the results (data not
shown). Data shown are representative of
three independent assays.
FIG. 4. Subcellular distribution of
the Vav CRD mutants. 293T cells
were transiently transfected with the
empty pAX142 mammalian expression
vector or pAX142 plasmids encoding the
N-186 VavCRD mutant proteins. For-
ty-eight hours after transfection, the cells
were lysed and subjected to high speed
centrifugation (100,000  g) to separate
into crude cytosolic (S100) and membrane
(P100) fractions. Twenty-five ng protein
of the total (T), cytosolic (S100), and mem-
brane (P100) fractions were resolved by
SDS-PAGE and protein expression was
determined by Western blot analysis us-
ing the anti-HA epitope antibody.
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caused a slight reduction in the amount of protein found in the
P100 fraction, both retained predominant association with the
P100 membrane-containing fraction (65%). The membrane-
targeted versions of both proteins, designated N-186 VavC
PH(K404A)-CX and N-186 VavC PH(W495L)-CX, showed
greatly increased association with the P100 crude membrane
fractions (80%) that was equivalent to that of the non-mu-
tated N-186 VavC protein. Fractionation studies done with
NIH 3T3 cells stably expressing the N-186 VavC PH mu-
tants yielded similar results (data not shown). These results
suggest that the PH domain may make a minor but significant
contribution to Vav membrane association.
We next performed NIH 3T3 focus formation assays to assess
the consequences of the PH domain mutations on Vav trans-
forming activity. For these analyses, we used pAX142 expres-
sion vectors encoding each of the PH domain mutants and
compared their activities with the oncogenic N-186 VavC
mutant protein (Fig. 6). Whereas the N-186 VavC
PH(K404A) mutant showed a greater than 30-fold reduction in
focus-forming activity, the N-186 VavC PH(W495L) mutant
showed a complete loss of transforming activity. Addition of a
membrane targeting sequence (N-186 VavC PH(K404A)-
CX) caused a partial 5-fold increase in transforming activity
that was still approximately only 30% of the activity seen with
the non-mutated protein. Thus, our data indicate the loss of
Vav transforming activity in N-186 VavC PH(K404A) may
be caused by a loss, in part, of PH domain-mediated membrane
association. In contrast, despite its strong association with
membranes, the membrane-targeted N-186 VavC
PH(W495L)-CX protein still lacked any detectable focus-form-
ing activity (Fig. 6). Finally, we compared the ability of the PH
domain mutants to stimulate transcriptional activation of c-
Jun, Elk-1, SRF, or NF-B, and we found that the degree of
stimulation seen with all transcription factors correlated with
transforming activity (Fig. 7). These observations suggest that
the PH domain may serve an additional role distinct from
facilitation of Vav association with membranes. Additionally,
because the PH domain mutants retained the CRD, these two
COOH-terminal domains must serve distinct roles in facilitat-
ing Vav signaling and transformation.
Vav PH Domain and CRD Are Not Sufficient for Membrane
Targeting—Our analyses above indicated that the requirement
for the PH domain and the CRD in Vav transformation may be
caused, in part, by facilitating membrane association. This
possibility is consistent with observations that the PH domain
(e.g. Akt) or CRD (e.g. PKC) of some signaling proteins do
function as membrane-targeting domains. Therefore, we eval-
uated the possibility that the isolated PH domain or CRD of
Vav could promote association with the plasma membrane.
For these analyses, we generated GFP-tagged fusion pro-
teins that contained either the isolated PH domain or the CRD,
or both (40). These were designated GFP-Vav PH, GFP-Vav
CRD, and GFP-Vav PH/CRD, respectively. We utilized GFP
fusion proteins containing the PH domain of Akt (GFP-AKT
PH) and the first CRD of PKC (GFP-PKC CRD) as positive
controls for these analyses. GFP-AKT PH has been shown to
localize to the plasma membrane in response to PI3K activa-
tion and formation of PIP3 (39, 45), whereas GFP-PKC CRD
FIG. 6. Mutation of the PH domain of Vav decreases Vav trans-
forming activity. NIH 3T3 cells were transfected with the empty
pAX142 plasmid or pAX142 plasmids encoding the various PH domain
mutants (1 g/60-mm dish). The appearance of transformed foci was
quantitated on day 14. The values represent the average 	 standard
error of three dishes and are representative of three independent
assays.
FIG. 5. Subcellular distribution of
the Vav PH domain mutants. 293T
cells were transiently transfected with
the empty pAX142 mammalian expres-
sion vector and pAX142 plasmids encod-
ing the various PH domain mutants. The
cultures were lysed 48 h after transfec-
tion and subjected to high speed centrifu-
gation (100,000  g) to separate cytosolic
and membrane fractions. Twenty-five ng
total protein for total (T), cytosolic (S100),
and membrane (P100) fractions were re-
solved by SDS-PAGE. Protein expression
was determined by Western blot analysis
using the anti-HA epitope antibody.
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localized to the plasma membrane upon treatment with the
diacylglycerol analog, phorbol myristic acid (40). We tran-
siently transfected NIH 3T3 cells with the expression plasmid
DNAs encoding the different GFP fusion proteins. In agree-
ment with previous studies, we found that both GFP-AKT PH
and GFP-PKC CRD showed strong localization to the plasma
membrane (Fig. 8). In contrast, cells expressing GFP-Vav PH,
GFP-Vav CRD, or GFP-Vav PH/CRD showed a diffuse cytoplas-
mic staining and lacked significant plasma membrane stain-
ing. Although it is possible that these domains may be mis-
folded in the GFP fusion proteins, their significant level of
expression in NIH 3T3 cells argue that this is not the case.
Thus, in contrast to related domains in other signaling pro-
teins, the PH domain and CRD of Vav, when expressed as
isolated domains, are not sufficient to function as plasma mem-
brane-targeting sequences. These results are also consistent
with our fractionation studies that showed that each domain
had limited roles in promoting Vav membrane association.
Phosphatidylinositol 3-Kinase Does Not Greatly Enhance
Vav Transformation or Signaling—Previous studies showed
that the products of PI3K, such as PIP3, can interact with the
PH domain and promote Vav catalytic activity in vitro (20, 21).
Additionally, it was shown that the PI3K substrate PIP2 pro-
moted the interaction of the PH domain with the DH domain,
thus inhibiting DH domain interaction with its GTPase sub-
strate (21). In contrast, PIP3 association with the PH domain
disrupted this association, leading to GTPase association with
the DH domain. These observations suggest that the activation
of PI3K should enhance the transforming and signaling prop-
erties of Vav.
Next, we wanted to determine whether co-expression of ac-
tivated PI3K would cause synergistic enhancement of Vav sig-
naling or transforming activity. These studies used p110-
CAAX, which is a plasma membrane-targeted fusion protein
containing the p110 catalytic subunit of PI3K. N-186 Vav
cooperated with p110-CAAX only modestly, resulting in 1.7-
fold increase over N-186 Vav alone (Fig. 9). Luciferase re-
porter assays were performed with SRF-Luciferase to deter-
mine whether signals downstream of Vav exchange activity
were enhanced in the presence of p110-CAAX. Again, only a
1.7-fold activation of SRF-luciferase was observed with N-186
Vav and p110-CAAX over N-186 Vav alone (Fig. 9). Together,
these data indicate that PI3K activation can cause a limited
enhancement of Vav function in vivo.
DISCUSSION
The invariant association of a PH domain with all DH do-
mains argues that the PH domain is critical for DH domain
function. Recent crystallographic determination of the struc-
tures of three different DH/PH domain fragments in complex
FIG. 8. The Vav PH domain and CRD are not sufficient to
target Vav to the plasma membrane. Serum-starved NIH 3T3 cells
transiently transfected with the empty pEGFP-C3 mammalian expres-
sion vector or pEGFP-C3 plasmids encoding Vav PH, Vav CRD or Vav
PH/CRD and pEGFP-C1/Akt PH or pEGFP-N1/PKC CRD as positive
controls were visualized with confocal microscopy.
FIG. 7. Mutation of the PH domain
of Vav decreases Vav signaling activ-
ity. NIH 3T3 cells were transiently trans-
fected with the empty pAX142 mamma-
lian expression vector or pAX142
plasmids encoding the various PH do-
main mutants (500 ng/30-mm dish), to-
gether with luciferase reporter plasmids
to determine the activation of c-Jun,
Elk-1, SRF, NF-B, and expression from
the cyclin D1 promoter. Data shown are
the average of duplicate plates and are
representative of at least three independ-
ent assays.
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with their respective Rho GTPase substrates indicates that
this role will vary significantly with different DH domains
(46–48). Whereas the PH domain is dispensable for DH do-
main GEF activity for Tiam1 and intersectin, it is necessary for
the DH domain GEF function of Dbs. Previous studies argued
that the PH domain was dispensable for the function of the Vav
and Vav3 DH domain and suggested that an adjacent CRD may
substitute for PH domain function. Therefore, in this study, we
have evaluated the roles of the PH domain and CRD in Vav
function. We found that, in contrast to the majority of other DH
domains, the Vav DH domain depends on the PH domain as
well as an adjacent CRD for biological activity. Although both
domains contribute to Vav membrane association, their func-
tions cannot be replaced with a plasma membrane targeting
sequence. This result contrasts observations made with two
other Dbl family proteins, where the PH domain was essential
for transforming activity and PH domain function could be
replaced by a plasma membrane targeting sequence. Further-
more, in contrast to the PH domain or CRD found in other
signaling proteins, the isolated or tandem PH domain or CRD
of Vav does not possess such membrane targeting activity.
Although there is evidence for functional differences between
Vav isoforms, our observations in this study, together with our
recent observations on Vav2 (23), argue that the PH domain
and CRD will have conserved functions in all Vav proteins.
Finally, we found that phosphoinositide binding may facilitate
Vav membrane association as well as modulate DH domain
function in vivo. Previous studies reached conflicting conclu-
sions regarding the importance of SH domains for Vav trans-
forming activity. Whereas missense mutation of the SH do-
mains caused a loss of activity (28, 29), deletion of the SH
domains indicated that these domains were dispensable for
transforming activity. The basis for these different observa-
tions is not known. In this study, we found that a missense
mutation in the COOH-terminal SH3 domain did impair Vav
activity, whereas a complete deletion of the entire SH3/SH2/
SH3 region did not abrogate Vav transformation. Bustelo and
colleagues (10) also made similar observations with Vav3, and
we recently found that the SH domains are dispensable for
Vav2 transforming activity as well (23). Therefore, our analy-
ses reveal the different consequences on biological activity
when a domain is mutated within the context of other domains
versus when the domains are deleted completely.
We found that Vav transforming and signaling were ablated
upon deletion of the CRD. Thus, in contrast to most other Dbl
family proteins, the minimal functional unit is not defined by
the tandem DH/PH domains alone. What role does the CRD
play in Vav function? We determined previously that the CRD
was also critical for the transforming activity of RasGRP, a
GEF for Ras proteins, and that a plasma membrane targeting
sequence could replace the CRD and restore RasGRP trans-
forming (33). However, we found that the loss of Vav trans-
forming activity caused by deletion of the CRD could not be
restored by addition of a plasma membrane targeting sequence.
Additionally, in contrast to the CRD of PKC, GFP-tagged Vav
CRD did not translocate to membranes in response to extracel-
lular stimuli. Thus, although these negative observations do
not define a role for the CRD in Vav function, they do show that
the CRD has a function distinct from the CRDs of other signal-
ing proteins. If the Vav CRD does not play a role in membrane
targeting, what other function might the CRD serve? Recently,
Bustelo and colleagues (13) observed that the CRD of Vav3
could bind to its GTPase substrates in vitro, and suggested that
the CRD may facilitate DH domain interaction with its sub-
strates. Consistent with this possibility, we recently observed
that mutation of the CRD impaired Vav2 catalytic activities in
vitro (23). However, because we have not been able to express
recombinant forms of the DH/PH and DH/PH/CRD peptides of
Vav, we have not been able to extend these observations to Vav.
Nevertheless, because our studies have determined that the
SH and PH domains, as well as the CRD, play identical roles in
Vav and Vav2 function, we speculate that the CRD of Vav will
also be important in facilitating DH domain interaction with
and activation of Rho GTPases.
We found that mutation of the PH domain, within the con-
text of an intact CRD, caused a loss of Vav signaling and
transforming activity. Similarly, we also found that the PH
domain is critical for the transforming activity of a constitu-
tively activated mutant of human Vav2 (23). Therefore, the PH
domain shares a common function in at least two different Vav
family proteins, and this function is distinct from that facili-
tated by the CRD. However, our results contrast with previous
studies that showed a negative regulatory (20, 22) or dispen-
sable function (13) for the PH domain of Vav and Vav3. One
FIG. 9. PI3K activation causes lim-
ited enhancement of N-186 Vav
transformation or signaling. A, SRF-
luciferase assays were done by transient
transfection of NIH 3T3 cells with pAX
142 empty vector or encoding N-186 Vav
(100 ng) and pcDNA3 empty vector or en-
coding p110-CAAX (500 ng) and SRF-lu-
ciferase (250 ng). Values shown are aver-
ages 	 standard error of three dishes and
are representative of four independent ex-
periments. B, NIH 3T3 focus formation
assays were done with empty pAX 142
vector or encoding N-186 Vav (50 ng)
and the empty pZIP-NeoSV(x)1 vector or
encoding p110-CAAX (500 ng). The num-
ber of foci of transformed cells was quan-
titated after 14 days. Values are the av-
erage 	 standard error of three dishes
and are representative of four independ-
ent assays.
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possible explanation for these different observations may be
that the previous studies mutated the PH domain in Vav con-
structs that retained other flanking domains such as the SH2
and SH3 domains. We assessed PH domain function in the
minimal functional unit of Vav proteins, the DH/PH/CRD frag-
ment, to avoid complications from other domains. Thus, what
we can conclude from our studies is that, similar to other Dbl
family proteins, the PH domain is a critical component of DH
domain function. It remains possible that, within the context of
full-length Vav, other domains may compensate for PH domain
function.
The PH domain has also been shown to be critical for the
function of other Dbl family proteins as well as other signaling
proteins. For some Dbl family proteins (Lfc and Dbs), deletion
or truncation of PH domain sequences resulted in complete loss
of transforming activity, and this defect could be restored by
the addition of the Ras COOH-terminal plasma membrane
targeting sequence (16, 17). In contrast, we found that the Ras
plasma membrane targeting sequence did not restore the loss
of function caused by the loss of function of the PH domain of
Vav. Thus, although this observation does not exclude the
possibility that the Vav PH domain does have membrane tar-
geting activity that is not accurately mimicked by the Ras
membrane targeting sequence, it does show that such a func-
tion is distinct from the membrane targeting function of the PH
domains of other Dbl family proteins. Finally, in contrast to the
PH domain of Akt, which alone can promote membrane target-
ing as a GFP fusion protein, we found that the PH domain of
Vav alone is not sufficient for plasma membrane targeting.
Although one trivial explanation for this negative result is that
the GFP fusion protein of the PH domain is misfolded, the lack
of a membrane targeting function is consistent with our frac-
tionation analyses that showed that the PH domain had a
limited role in facilitating Vav association with membranes. It
is also consistent with observations by us (49) and others that
the critical structural determinants required for high affinity
binding to phosphoinositides are absent from the PH domains
of Dbl family proteins (50, 51). Thus, these PH domains are not
expected to function as efficient membrane targeting domains.
Therefore, we feel that our results do suggest that the PH
domain of Vav has a function that is distinct from that of the
PH domain of Akt.
The issue of whether PI3K-generated phosphoinositides can
promote the activation of Dbl family proteins is controversial.
Although there are reports in the literature that PIP3 can
activate some Dbl family proteins, our recent analyses in vitro
indicates that this will not involve regulation of the intrinsic
catalytic function of the DH domain (49). We observed that the
reduction in transforming activity caused by the K404A PH
domain mutation, which impairs PIP3 binding (20), could be
restored partially by the addition of a membrane targeting
sequence. Thus, although the Vav PH domain alone is not
sufficient to promote membrane association, it may still facili-
tate PIP3-dependent membrane association in conjunction with
the DH domain and CRD interaction with membrane-associ-
ated Rho GTPases. Based on the limited stimulation of Vav
activity seen with PI3K activation, this membrane association
may further promote DH domain activity in vivo. However,
because the complete loss of transforming activity seen with a
second PH domain mutant (W495L) could not be restored by
the addition of a membrane targeting sequence, it argues that
the PH domain must contribute a second essential function
independent of membrane association.
The Vav PH domain may also be required for the full cata-
lytic function of the DH domain. A comparison of the catalytic
activity of the DH and DH/PH domains derived from several
Dbl family proteins (e.g. Trio, Dbs) showed that the PH domain-
containing protein exhibited up to 100-fold greater GEF activ-
ity than measured for the DH domain alone in vitro (52, 53).
However, we found that mutation of the PH domain of Vav2
impaired its function in vivo, but did not impair DH domain
catalytic activity in vitro (23). Thus, the PH domain of Vav
must serve some other function, in addition to facilitating
membrane association, in vivo.
In summary, although Vav has been one of the most in-
tensely studied Dbl family proteins, much remains unresolved
concerning its regulation. In particular, there have been con-
siderable discrepancies in the literature concerning the role of
the COOH-terminal domains of Vav in regulation of GEF cat-
alytic activity and biological function. Our studies have cer-
tainly not reached a clear conclusion regarding their functions.
However, we feel that our detailed analyses of both Vav and
Vav2, using similar assays and experimental approaches, have
provided more definitive information with regards to how the
PH domain and CRD act in regulating the catalytic activity of
the DH domain. What is also clear from our studies is that,
when compared with our similar analyses of other Dbl family
proteins, the PH domain serves functions in Vav, which are
very different than what has described for the PH domains for
other Dbl family members. For Vav proteins, it is now clear
that membrane localization is not the only role of the PH
domain and CRD. In addition, whether activation of PI3K will
cause regulation of Dbl proteins via the PH domain is not a
simple issue, and PI3K is likely to have very different roles in
regulating the activities of other Dbl family proteins. It is now
clear that simple and general models will not be adequate to
explain the complex and diverse mechanisms by which DH
domain function will be regulated in different Dbl family
proteins.
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